Pulse Biosciences, Inc.
PLSE
$20.86
-$0.07-0.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.89% | 79.99% | 86.38% | 74.51% | 51.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.39% | 62.86% | 56.60% | 42.71% | 29.11% |
| Operating Income | -36.76% | -62.68% | -56.60% | -42.71% | -29.11% |
| Income Before Tax | -35.82% | -61.99% | -54.54% | -41.59% | -26.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.82% | -61.99% | -54.54% | -41.59% | -26.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.82% | -61.99% | -54.54% | -41.59% | -26.95% |
| EBIT | -36.76% | -62.68% | -56.60% | -42.71% | -29.11% |
| EBITDA | -37.74% | -64.47% | -58.26% | -43.99% | -30.00% |
| EPS Basic | -20.46% | -41.74% | -35.43% | -21.92% | -1.93% |
| Normalized Basic EPS | -20.47% | -41.73% | -35.45% | -21.92% | -1.91% |
| EPS Diluted | -20.46% | -41.74% | -35.43% | -21.92% | -1.93% |
| Normalized Diluted EPS | -20.47% | -41.73% | -35.45% | -21.92% | -1.91% |
| Average Basic Shares Outstanding | 13.54% | 14.50% | 13.83% | 15.01% | 21.51% |
| Average Diluted Shares Outstanding | 13.54% | 14.50% | 13.83% | 15.01% | 21.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |